NCT02968004Phase 3Completed

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Study sponsor: OPKO Health, Inc. · OPK

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2019-08Actual
Enrollment · participants224Actual
Source updated2025-07-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview